Abstract

DESIGN AND INVITRO EVALUATION OF “NON ERODIBLE POLYMERIC MATRIX TABLETS OF ISONIAZID USING SINTERING TECHNIQUE

*Raju. Manda, Virajaji Kaya, Bonagiri Sreedevi, Rachamalla Sai Santhosh and
Dr.R.Suthakaran

Abstract

Tuberculosis rampant infectious disease is considered to be the foremost cause of death caused by Mycobacterium tuberculi. Isoniazid (300 mg) i s a one o f t h e mo s t important “first line” drug recommended by World Health Organization (WHO) for the treatment of tuberculosis. Isoniazid and different proportions of additives were mixed. Tablets containing 300 mg equivalent to Isoniazid were compressed (surface lubricated with magnesium stearate) on sixteen punch tableting compression machine. From the invitro dissolution data, it can be concluded that Eudragit RL 100 had retarding capacity of drug from being released. This retardant capacity was more in E4 sintered at 4.5 hr as compared to all other formulations and release kinetics model follows Higuchi diffusion model. No statistically significant differences were observed the release profile of optimized formulation E4 sintered at 4.5 hr and also release kinetics were unaltered lastly no significant physical characteristics were changed when stability study was done for three months 400C ±20C at 75% RH & ±5%RH. From the above it was concluded that formulation E4 sintered at 4.5 hr was stable in short term stability study.

Keywords: Isoniazid, Higuchi diffusion model, Eudragit RL 100, Dibasic calcium phosphate, direct compression method.